hematology and oncology
Cancer Screening
Introduction
Cancer can sometimes be detected in asymptomatic patients via regular physical examinations and screening tests. (See also Overview of Cancer .) Physical examinations for cancers of the thyroid, oral cavity, skin, lymph nodes, testes, prostate, cervix, and ovaries should be a part of routine medical care. Screening Tests None Screening for cancer should be done in the following circumstances: When distinct high-risk groups can be identified such as people who have a family history of breast, ovarian, pancreatic, hematologic, colonic, or prostate cancers When a screening test is proved to have a benefit that exceeds risk and is recommended by competent health authorities Recommended screening schedules are constantly evolving based on ongoing studies (see table Screening Procedures in Average-Risk* Asymptomatic People as Recommended by the American Cancer Society (ACS), US Preventive Services Task Force (USPSTF), and American College of Physicians (ACP)† ). Current considerations regarding screening include the developing understanding that some findings (particularly in prostate and breast tissues) that appear cancerous may not actually progress to cancer within a person's remaining lifetime. For example, routine screening for blood levels of prostate-specific antigen (PSA) in men and routine screening mammograms in women may result in biopsy findings that a pathologist considers a cancer but that will not manifest clinically as a cancer or that manifest as a cancer that does not adversely affect survival. In such cases, people may receive cancer treatments (eg, surgery, chemotherapy, radiation therapy) that do not benefit them. The key issue in screening is how many people need to be screened to prevent one cancer death and how many people will receive unnecessary interventions or be given unnecessary concern. Because of these complexities, there is considerable controversy regarding who should be screened and at what ages for what cancers. Recommendations from theAmerican Cancer Society(ACS), theUS Preventive Services Task Force(USPSTF), and various subspecialty organizations may differ. The American College of Physicians (ACP) offers recommendations based on a review of existing guidelines and the evidence they include forbreast cancerandcolon cancerscreening. Type of Cancer Type of Cancer Procedure Procedure Frequency Frequency Breast cancer Mammography ACS: Recommended at the following ages: 40 to 44: Optional 45 to 54: Yearly ≥ 55: Every 1 to 2 years, continued as long as women are expected to live ≥ 10 years USPSTF: Every 2 years for women ages 50 to 74 ACP: Recommended at the following ages: 40 to 49: Optional, after discussing potential benefits and harms (but for most women, harms outweigh benefits) 50 to 74: Every 2 years ≥ 75 or women with a life expectancy of 10 years or less: Discontinue screening Cervical cancer Papanicolaou (Pap) test and/or human papillomavirus (HPV) test ACS: Recommended at the following ages: < 25: No screening tests 25–65: HPV test alone every 5 yearsorPap test plus HPV test every 5 yearsorPap test every 3 years > 65: No testing if previous testing was done and results were normal USPSTF: Recommended at the following ages: 21 to 29: Cervical cytology alone every 3 years 30 to 65: Cervical cytology alone every 3 yearsorhuman papillomavirus (HPV) testing alone or combined with cytology (co-testing) every 5 years. > 65: No testing if previous testing was done and results were normal Prostate cancer Blood test for PSA (prostate-specific antigen) ACS: Because the benefit of screening is uncertain, patient and physician should discuss the potential harms and benefits of prostate cancer screening beginning at age 50 (age 45 for African Americans or those who have a father or brother who had prostate cancer before age 65) USPSTF: The patient and physician should discuss the potential harms and benefits of prostate cancer screening beginning at age 55, but recommends against screening at age 70 or older. Colorectal cancer Stool testing: Fecal immunochemical test (FIT), high-sensitivity guaiac fecal occult blood test (gFOBT), or multi-target stool DNA test or Colonoscopy or Flexible sigmoidoscopy (with or without periodic FIT) or CT colonography ACS: Ages for screening: Begin at age 45 and continue until age 75; at ages 76-85, individualize recommendation (eg, based on general health, life expectancy, and patient preferences) ACS: Screening tests: FIT or gFOBT every year or Multi-target stool DNA test every 3 years, or Colonoscopy every 10 years, or CT colonography or flexible sigmoidoscopy every 5 years USPSTF: Ages for screening: 45 to 75; individualize for ages 76 to 85. USPSTF: Screening tests: Same as ACS, as well as flexible sigmoidoscopy every 10 years plus FIT every year ACP: Ages: Recommended for ages 50 to 75; not recommended for age > 75 or with life expectancy < 10 years ACP: Screening tests: FIT or gFOBT every 2 years, or Colonoscopy every 10 years, or Flexible sigmoidoscopy every 10 years plus fecal immunochemical testing every 2 years * Patients at high-risk of certain cancers may need to be screened according to a different schedule. For example, the ACS recommends that patients ages 55 to 74 at high risk for lung cancer, such as smokers with a 30 pack year history, who have smoked withing the last 15 years, and who are otherwise in good health, undergo periodic screening with low dose CT. The USPSTF recommends similar screening until age 80. † Examinations for cancers of the thyroid, oral cavity, skin, lymph nodes, testes, and ovaries should also be done during routine medical care. Modified from the recommendations of theUnited States Preventative Services Task Force(USPSTF), theAmerican Cancer Society(ACS), the American College of Physicians (ACP) recommendations forbreast cancerandcolon cancerscreening. 